D. E. Shaw & Co., Inc. Infla Rx N.V. Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.78 - $1.9 $18,065 - $44,005	-23,161 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.83 - $4.48 $7,122 - $17,436	-3,892 Reduced 14.39%	23,161 $42,000
Q4 2021 Feb 14, 2022	BUY	$2.35 - $5.58 $63,574 - $150,955	27,053 New	27,053 $129,000
Q3 2020 Nov 16, 2020	SELL	$3.7 - $5.47 $97,372 - $143,953	-26,317 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$4.59 - $8.96 $120,795 - $235,800	26,317 New	26,317 $121,000
Q3 2019 Nov 14, 2019	SELL	$2.47 - $3.51 $209,611 - $297,869	-84,863 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$3.06 - $51.61 $48,843 - $823,798	15,962 Added 23.17%	84,863 $268,000
Q1 2019 May 15, 2019	BUY	$31.16 - $48.62 $1.66 Million - $2.59 Million	53,353 Added 343.15%	68,901 $2.6 Million
Q4 2018 Feb 14, 2019	SELL	$23.33 - $36.37 $171,755 - $267,755	-7,362 Reduced 32.13%	15,548 $565,000
Q3 2018 Nov 14, 2018	SELL	$29.34 - $35.0 $80,685 - $96,250	-2,750 Reduced 10.72%	22,910 $786,000
Q2 2018 Aug 14, 2018	BUY	$27.33 - $41.46 $701,287 - $1.06 Million	25,660 New	25,660 $828,000

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $90.2M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.